Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) submitted its Monthly Return to the Hong Kong Stock Exchange for the period ended 31 May 2026, confirming that both authorised and issued share capital remained unchanged during the month.

Authorised / registered capital • H-shares: 0.26 billion shares at RMB 1 par value, unchanged from April 2026. • A-shares: 6.38 billion shares at RMB 1 par value, unchanged. • Total authorised capital: RMB 6.64 billion.

Issued shares and treasury position • H-shares in issue: 0.26 billion; no treasury shares outstanding. • A-shares in issue: 6.37 billion; treasury shares: 6.90 million. • No new shares were issued, repurchased, or cancelled in either class during May.

Public-float compliance • H-share public float was 3.89%, with a market value of HK$17.56 billion, exceeding the Main Board’s HK$1 billion threshold and confirming compliance with Listing Rule 19A.28D(1).

Employee share schemes • Up to 6.90 million A-shares remain available for transfer under the company’s 2022–2025 A-Share Employee Stock Ownership Schemes; no transfers occurred in May.

No outstanding share options, warrants, or convertible securities were reported, and no other share movements took place during the month.